{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:25Z","timestamp":1792791445675,"version":"4.5.0"},"reference-count":114,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alpine Immune Sciences Inc.","id":[{"id":"https:\/\/ror.org\/004sp0722","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanofi","id":[{"id":"https:\/\/ror.org\/02n6c9837","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medison"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The McMaster Immune Thrombocytopenia (ITP) Summit, held on October 27, 2023, was an educational seminar from leading experts in immune thrombocytopenia and related disorders geared toward hematologists, internists, immunologists, and clinical and translational scientists. The focus of the Summit was to review the mechanisms, diagnosis, and treatment of primary versus secondary ITP. Specific objectives were to describe the unique features of secondary ITP, and to review its mechanisms in the context of autoimmune disease and infection. The key messages in this Summit were: (1) ITP is a heterogeneous disease, and genetic and immunologic insights may help classify patient subtypes; (2) exploring the autoimmune mechanisms and their association with hypogammaglobulinemia in patients with secondary ITP could improve our understanding of ITP and its subtypes; (3) investigating the mechanisms of ITP in the context of infections caused by viruses such as CMV, HIV, dengue, and hepatitis C, or bacteria such as H. pylori, or vaccinations could provide insight into the causes of ITP. A better understanding of secondary ITP could help elucidate the pathogenesis of ITP.<\/jats:p>","DOI":"10.1055\/a-2508-1112","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:00:21Z","timestamp":1735066821000},"page":"923-932","source":"Crossref","is-referenced-by-count":6,"title":["Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-4179","authenticated-orcid":false,"given":"Dimpy","family":"Modi","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifur R.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"},{"name":"Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3496-4591","authenticated-orcid":false,"given":"Syed","family":"Mahamad","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Modi","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Cines","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy E.","family":"Neunert","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Moulis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Liebman","sequence":"additional","affiliation":[{"name":"University of Southern California-Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Bussel","sequence":"additional","affiliation":[{"name":"Platelet Research & Treatment Program Weill, Cornell Medicine, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky R.","family":"Breakey","sequence":"additional","affiliation":[{"name":"McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"103677","DOI":"10.1016\/j.autrev.2024.103677","article-title":"Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP)","volume":"23","author":"Q Li","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2008-09-181073","article-title":"Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia","volume":"113","author":"W Zhang","year":"2009","journal-title":"Blood"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.1996.d01-1872.x","article-title":"Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)","volume":"95","author":"J F Wright","year":"1996","journal-title":"Br J Haematol"},{"issue":"26","key":"ref4","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"D B Cines","year":"2009","journal-title":"Blood"},{"issue":"22","key":"ref5","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"G Moulis","year":"2014","journal-title":"Blood"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.24702","article-title":"Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort","volume":"92","author":"G Moulis","year":"2017","journal-title":"Am J Hematol"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry","volume":"1","author":"D M Arnold","year":"2017","journal-title":"Blood Adv"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.19083","article-title":"Pathogenesis of refractory ITP: overview","volume":"203","author":"D B Cines","year":"2023","journal-title":"Br J Haematol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood.2022018568","article-title":"TORing the impact of sirolimus on immune health","volume":"141","author":"K Gollomp","year":"2023","journal-title":"Blood"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1182\/bloodadvances.2023009949","article-title":"Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP","volume":"7","author":"J A Georgi","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"ref12","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ajh.26900","article-title":"Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia","volume":"98","author":"T Pincez","year":"2023","journal-title":"Am J Hematol"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Z Guitton","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/bloodadvances.2019000400","article-title":"Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance","volume":"3","author":"M A Hollenhorst","year":"2019","journal-title":"Blood Adv"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.19078","article-title":"Novel therapeutics and future directions for refractory immune thrombocytopenia","volume":"203","author":"H Al-Samkari","year":"2023","journal-title":"Br J Haematol"},{"issue":"30","key":"ref17","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level","volume":"101","author":"R J Ober","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"D C Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"P Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"A C Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"C M Broome","year":"2023","journal-title":"Lancet"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1189\/jlb.0513307","article-title":"Bruton's tyrosine kinase\u2014an integral protein of B cell development that also has an essential role in the innate immune system","volume":"95","author":"G L\u00f3pez-Herrera","year":"2014","journal-title":"J Leukoc Biol"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"C L Langrish","year":"2021","journal-title":"J Immunol"},{"issue":"15","key":"ref25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"D J Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"D J Kuter","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"T D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"A M Risitano","year":"2021","journal-title":"Lancet Haematol"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"X Liu","year":"2023","journal-title":"Lancet Haematol"},{"issue":"S 01","key":"ref31","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/blood-2021-151410","article-title":"Daratumumab as a treatment for adult immune thrombocytopenia: a phase II study with safety run-in (the DART Study)","volume":"138","author":"G Tsykunova","year":"2021","journal-title":"Blood"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"E R Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e691820b","DOI":"10.1097\/01.HS9.0000976912.69182.0b","article-title":"PB2554: design of a phase 1B open-label study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of povetacicept (ALPN-303) in subjects with autoimmune cytopenias (RUBY-4)","volume":"7","author":"C M Broome","year":"2023","journal-title":"HemaSphere"},{"issue":"10","key":"ref34","first-page":"e30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"M A Ameer","year":"2022","journal-title":"Cureus"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial","volume":"5","author":"M Shipa","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"L E R\u00f6nnblom","year":"1991","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"A Psarras","year":"2020","journal-title":"Nat Commun"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1358\/dot.2023.59.2.3521876","article-title":"Anifrolumab in systemic lupus erythematosus","volume":"59","author":"M F Loncharich","year":"2023","journal-title":"Drugs Today (Barc)"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"A Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref40","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"M Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/annrheumdis-2020-217013","article-title":"Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study","volume":"79","author":"F X Zhu","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1136\/annrheumdis-2020-219470","article-title":"Correspondence on \u201cRisk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study\u201d","volume":"82","author":"J Maquet","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bjh.19069","article-title":"Clinical significance of antinuclear antibodies in primary immune thrombocytopenia","volume":"203","author":"G Moulis","year":"2023","journal-title":"Br J Haematol"},{"issue":"22","key":"ref44","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2014-04-570127","article-title":"Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis","volume":"124","author":"K MJ Heitink-Poll\u00e9","year":"2014","journal-title":"Blood"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/16078454.2020.1740430","article-title":"The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia","volume":"25","author":"Y M Wang","year":"2020","journal-title":"Hematology"},{"issue":"01","key":"ref46","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"C Arnal","year":"2002","journal-title":"J Rheumatol"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ard.2004.033100","article-title":"Lupus thrombocytopenia: clinical implications and prognostic significance","volume":"64","author":"P D Ziakas","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref48","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/rheumatology\/keab925","article-title":"Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients","volume":"61","author":"M Roussotte","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"A Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"M Khellaf","year":"2014","journal-title":"Am J Hematol"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/ajh.24698","article-title":"Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP)","volume":"92","author":"O Roche","year":"2017","journal-title":"Am J Hematol"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"A Serris","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","article-title":"Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study","volume":"39","author":"F Sun","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/rheumatology\/kead160","article-title":"Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study","volume":"63","author":"H Du","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.31138\/mjr.33.4.444","article-title":"Successful treatment of systemic lupus erythematosus-associated thrombocytopenia with eltrombopag: a report of two cases and literature review","volume":"33","author":"F Uluta\u015f","year":"2022","journal-title":"Mediterr J Rheumatol"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"e32949","DOI":"10.1097\/MD.0000000000032949","article-title":"Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review","volume":"102","author":"W Garra","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.rpth.2023.100125","article-title":"Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag","volume":"7","author":"S Van de Vondel","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.18773","article-title":"B cells and antibodies in refractory immune thrombocytopenia","volume":"203","author":"A Roeser","year":"2023","journal-title":"Br J Haematol"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"E S Resnick","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical picture and treatment of 2212 patients with common variable immunodeficiency","volume":"134","author":"B Gathmann","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: defining subgroups in common variable immunodeficiency","volume":"111","author":"C Wehr","year":"2008","journal-title":"Blood"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clim.2008.02.013","article-title":"Memory B cells in common variable immunodeficiency: clinical associations and sex differences","volume":"128","author":"S S\u00e1nchez-Ram\u00f3n","year":"2008","journal-title":"Clin Immunol"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clim.2007.04.012","article-title":"High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency","volume":"124","author":"A K Knight","year":"2007","journal-title":"Clin Immunol"},{"issue":"302","key":"ref64","doi-asserted-by":"crossref","first-page":"302ra135","DOI":"10.1126\/scitranslmed.aab1216","article-title":"IgH sequences in common variable immune deficiency reveal altered B cell development and selection","volume":"7","author":"K M Roskin","year":"2015","journal-title":"Sci Transl Med"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2249.2012.04643.x","article-title":"T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections","volume":"170","author":"E AL Bateman","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10875-021-01084-6","article-title":"Chronically activated T-cells retain their inflammatory properties in common variable immunodeficiency","volume":"41","author":"R M Berbers","year":"2021","journal-title":"J Clin Immunol"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood.2019000929","article-title":"Current genetic landscape in common variable immune deficiency","volume":"135","author":"H Abolhassani","year":"2020","journal-title":"Blood"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"786516","DOI":"10.3389\/fimmu.2021.786516","article-title":"Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: experience from a monocentric study","volume":"12","author":"J Rojas-Restrepo","year":"2021","journal-title":"Front Immunol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1272912","DOI":"10.3389\/fgene.2023.1272912","article-title":"Genetics and clinical phenotypes in common variable immunodeficiency","volume":"14","author":"C Cunningham-Rundles","year":"2024","journal-title":"Front Genet"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaut.2005.04.006","article-title":"Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID)","volume":"25","author":"J Wang","year":"2005","journal-title":"J Autoimmun"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"D Gobert","year":"2011","journal-title":"Br J Haematol"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10875-016-0282-5","article-title":"Use of thrombopoietin-receptor agonist in CVID-associated immune thrombocytopenia","volume":"36","author":"M Carrabba","year":"2016","journal-title":"J Clin Immunol"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cei.12039","article-title":"Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients","volume":"172","author":"G K Wong","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJM194708142370704","article-title":"Chicken pox with simultaneous idiopathic thrombocytopenic purpura; report of a case","volume":"237","author":"J J Cohen","year":"1947","journal-title":"N Engl J Med"},{"issue":"25","key":"ref75","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM196512162732504","article-title":"Purpura in congenital and acquired rubella","volume":"273","author":"W L Bayer","year":"1965","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"D B Cines","year":"2009","journal-title":"Semin Hematol"},{"issue":"9131","key":"ref77","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(05)60004-9","article-title":"Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori","volume":"352","author":"A Gasbarrini","year":"1998","journal-title":"Lancet"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review","volume":"113","author":"R Stasi","year":"2009","journal-title":"Blood"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2003-03-0900","article-title":"Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?","volume":"103","author":"M Michel","year":"2004","journal-title":"Blood"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/vim.2021.0135","article-title":"Dengue virus and platelets: from the biology to the clinic","volume":"35","author":"P X Losada","year":"2022","journal-title":"Viral Immunol"},{"issue":"05","key":"ref81","first-page":"e61090","article-title":"Papaya leaf extract elevates platelet levels in individuals with dengue fever","volume":"16","author":"R Haward","year":"2024","journal-title":"Cureus"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-96-6-714","article-title":"Autoimmune thrombocytopenic purpura in homosexual men","volume":"96","author":"L Morris","year":"1982","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-107-4-474","article-title":"Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study","volume":"107","author":"R A Kaslow","year":"1987","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.1992.tb00591.x","article-title":"Epidemiology of thrombocytopenia in HIV infection","volume":"48","author":"E M Sloand","year":"1992","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.1992.tb06476.x","article-title":"Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men","volume":"82","author":"G H Mientjes","year":"1992","journal-title":"Br J Haematol"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00042560-199704010-00011","article-title":"Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project","volume":"14","author":"P S Sullivan","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jmv.1890420106","article-title":"Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort)","volume":"42","author":"J F Quaranta","year":"1994","journal-title":"J Med Virol"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00000441-200008000-00010","article-title":"Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia","volume":"320","author":"D M Aboulafia","year":"2000","journal-title":"Am J Med Sci"},{"issue":"03","key":"ref89","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00042560-200111010-00003","article-title":"HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy","volume":"28","author":"J Servais","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"06","key":"ref90","first-page":"593","article-title":"Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia","volume":"4","author":"M U Rarick","year":"1991","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-103-4-542","article-title":"Thrombocytopenia in homosexual patients. Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome","volume":"103","author":"C Walsh","year":"1985","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V82.1.29.bloodjournal82129","article-title":"Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia","volume":"82","author":"E Oksenhendler","year":"1993","journal-title":"Blood"},{"issue":"08","key":"ref93","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients","volume":"89","author":"A Scaradavou","year":"1997","journal-title":"Blood"},{"key":"ref94","first-page":"910954","article-title":"Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era","volume":"2012","author":"K LS Ambler","year":"2012","journal-title":"Adv Hematol"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2325957414557266","article-title":"Initial experience with the use of thrombopoetin receptor agonists in patients with refractory HIV-associated immune thrombocytopenic purpura: a case series","volume":"14","author":"M Kowalczyk","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-121-6-199409150-00005","article-title":"Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial","volume":"121","author":"M Marroni","year":"1994","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2141.2000.02132.x","article-title":"HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant \u03b12b-interferon therapy","volume":"110","author":"J Garc\u00eda-Su\u00e1rez","year":"2000","journal-title":"Br J Haematol"},{"issue":"03","key":"ref98","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ajh.1180","article-title":"Treatment of hepatitis C related thrombocytopenia with interferon alpha","volume":"68","author":"S Rajan","year":"2001","journal-title":"Am J Hematol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bmj.299.6704.871","article-title":"The elusive hepatitis C virus","volume":"299","author":"A J Zuckerman","year":"1989","journal-title":"BMJ"},{"issue":"10","key":"ref100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"G L Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11894-001-0044-1","article-title":"Extrahepatic manifestations of chronic viral hepatitis","volume":"3","author":"N T Pyrsopoulos","year":"2001","journal-title":"Curr Gastroenterol Rep"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005792-200001000-00005","article-title":"Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C","volume":"79","author":"P Cacoub","year":"2000","journal-title":"Medicine (Baltimore)"},{"issue":"01","key":"ref103","first-page":"23","article-title":"Burden, outcome, and comorbidities of extrahepatic manifestations in hepatitis C virus infection","volume":"12","author":"B Songtanin","year":"2022","journal-title":"Biology (Basel)"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/asheducation-2008.1.212","article-title":"Viral-associated immune thrombocytopenic purpura","volume":"x","author":"H A Liebman","year":"2008","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2005.05542.x","article-title":"Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura","volume":"129","author":"S K Rajan","year":"2005","journal-title":"Br J Haematol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S186106","article-title":"Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia","volume":"15","author":"T A Elbedewy","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"03","key":"ref107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"N Terrault","year":"2018","journal-title":"Gastroenterology"},{"issue":"01","key":"ref108","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.30900","article-title":"Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals","volume":"71","author":"Y Johira","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref109","doi-asserted-by":"crossref","first-page":"2161498","DOI":"10.1080\/09537104.2022.2161498","article-title":"Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb\/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia","volume":"34","author":"T Satoh","year":"2023","journal-title":"Platelets"},{"issue":"12","key":"ref110","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.4254\/wjh.v7.i12.1718","article-title":"Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: a case report and systematic review of literature","volume":"7","author":"R Arena","year":"2015","journal-title":"World J Hepatol"},{"issue":"07","key":"ref111","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM196608182750703","article-title":"Effect of live measles vaccine on the platelet count","volume":"275","author":"F A Oski","year":"1966","journal-title":"N Engl J Med"},{"issue":"03","key":"ref112","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1651-2227.1993.tb12657.x","article-title":"Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients","volume":"82","author":"U Nieminen","year":"1993","journal-title":"Acta Paediatr"},{"key":"ref113","volume-title":"Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality","author":"K R Stratton","year":"1994"},{"issue":"04","key":"ref114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management","volume":"156","author":"E Mantadakis","year":"2010","journal-title":"J Pediatr"},{"issue":"16","key":"ref115","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"C Neunert","year":"2011","journal-title":"Blood"},{"issue":"07","key":"ref116","first-page":"e41460","article-title":"Comparative analysis of de novo immune thrombocytopenia following mRNA COVID-19 vaccine versus non-mRNA vaccines and COVID-19: a global database analysis","volume":"15","author":"M Mericliler","year":"2023","journal-title":"Cureus"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2508-1112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T22:37:21Z","timestamp":1755902241000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2508-1112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":114,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,8,22]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2508-1112","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,24]]},"published":{"date-parts":[[2024,12,24]]}}}